查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553623

脂質體阿黴素市場規模、佔有率、趨勢分析報告：按產品、按應用、按分銷管道、按地區、細分市場預測，2024-2030 年

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

脂質體阿黴素市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計2030年全球脂質體阿黴素市場規模將達18.9億美元，2024年至2030年複合年成長率為6.3%。

等待美國FDA 和歐洲藥品管理局核准的各種研發線產品的存在是該市場的關鍵特徵之一。第一個脂質體阿黴素製劑於 1995 年推出。來自 Janssen Products 的 Doxil/Caelyx 以及來自 Teva Pharmaceutical Laboratories 的 LP & Myocet。 Doxil是脂質體阿黴素的品牌名稱，目前正在開發中，預計一旦商業化，將在未來三到四年內產生巨大的價值。

美國FDA 藥品生產核准的增加預計也將提振市場。這些藥物用於治療多種疾病的適應症不斷擴大，包括與愛滋病相關的卡波西氏肉瘤、多發性骨髓瘤、神經母細胞瘤、骨癌和卵巢癌，這意味著需求的成長。克服不良健康影響的藥物配方技術進步以及各種類型的藥物傳輸系統（例如塗層奈米顆粒）的採用是推動藥物需求的一些關鍵因素。

脂質體阿黴素主要核准用於治療骨髓瘤、卡波西氏肉瘤和卵巢癌。然而，由於它也廣泛用於其他疾病，2015年乳癌的收益佔比最高，達21.2%。乳癌盛行率的增加導致對化療的需求增加，化療佔了收益佔有率的大部分。除了乳癌之外，卵巢癌、多發性骨髓瘤、肝癌在2015年也佔了很大的佔有率。阿黴素在肝癌治療中的應用正在迅速擴大，預計在預測期內該應用將以 7.8% 的最快複合年成長率成長。

脂質體阿黴素市場報告亮點

  • 增加技術先進的阿黴素製劑臨床試驗的併購和合作夥伴關係將支持市場成長。
  • 亞太地區增加研發投資、改善醫療基礎設施以及提高患者對標靶癌症治療和化療的認知將推動該地區的市場成長。
  • 預計到 2023 年，Lipodox 製劑將佔據 40.0% 的佔有率，2024 年至 2030 年複合年成長率為 7.3%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章脂質體阿黴素市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 脂質體阿黴素市場分析工具
    • 波特的分析
    • PESTEL分析

第4章脂質體阿黴素市場：依產品估計和趨勢分析

  • 細分儀表板
  • 脂質體阿黴素市場：2023 年和 2030 年產品變化分析
  • Doxil/caerix
  • 脂質體
  • 米奧塞特
  • 其他

第5章脂質體阿黴素市場：應用、估計和趨勢分析

  • 細分儀表板
  • 脂質體阿黴素市場：2023 年和 2030 年應用變化分析
  • 乳癌
  • 卵巢癌
  • 愛滋病相關的卡波西氏肉瘤
  • 多發性骨髓瘤
  • 其他

第6章脂質體阿黴素市場：按分銷管道估算和趨勢分析

  • 細分儀表板
  • 脂質體阿黴素市場：2023 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章脂質體阿黴素市場：區域、估計和趨勢分析

  • 2023年及2030年脂質體阿黴素市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Sun Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Cipla
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
    • Lupin
    • Cadila Pharmaceuticals
    • SRS Life Sciences
    • GSK plc.
    • Pfizer Inc.
    • Sanofi
    • Sigma-Aldrich Co.
簡介目錄
Product Code: GVR-1-68038-743-8

Liposomal Doxorubicin Market Growth & Trends:

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

Liposomal Doxorubicin Market Report Highlights:

  • The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
  • Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
  • The lipodox segment dominated the market with 40.0% share in 2023 and is expected to grow at a CAGR of 7.3% from 2024 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Liposomal Doxorubicin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liposomal Doxorubicin Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Doxil/Caelyx
    • 4.3.1. Doxil/Caelyx Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lipodox
    • 4.4.1. Lipodox Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Myocet
    • 4.5.1. Myocet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liposomal Doxorubicin Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Breast Cancer
    • 5.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Ovarian Cancer
    • 5.4.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. AIDS-Related Kaposi's Sarcoma
    • 5.5.1. AIDS-Related Kaposi's Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Multiple Myeloma
    • 5.6.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Solid Tumors
    • 5.7.1. Other Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Liposomal Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

  • 7.1. Liposomal Doxorubicin Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Recent Developments & Impact Analysis by Key Market Participants
  • 7.8. Company Categorization
  • 7.9. Company Heat Map Analysis
  • 7.10. Company Profiles
    • 7.10.1. Sun Pharmaceutical Industries Ltd.
      • 7.10.1.1. Participant's Overview
      • 7.10.1.2. Financial Performance
      • 7.10.1.3. Product Benchmarking
      • 7.10.1.4. Recent Developments/ Strategic Initiatives
    • 7.10.2. Johnson & Johnson Services, Inc.
      • 7.10.2.1. Participant's Overview
      • 7.10.2.2. Financial Performance
      • 7.10.2.3. Product Benchmarking
      • 7.10.2.4. Recent Developments/ Strategic Initiatives
    • 7.10.3. Merck & Co., Inc.
      • 7.10.3.1. Participant's Overview
      • 7.10.3.2. Financial Performance
      • 7.10.3.3. Product Benchmarking
      • 7.10.3.4. Recent Developments/ Strategic Initiatives
    • 7.10.4. Cipla
      • 7.10.4.1. Participant's Overview
      • 7.10.4.2. Financial Performance
      • 7.10.4.3. Product Benchmarking
      • 7.10.4.4. Recent Developments/ Strategic Initiatives
    • 7.10.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
      • 7.10.5.1. Participant's Overview
      • 7.10.5.2. Financial Performance
      • 7.10.5.3. Product Benchmarking
      • 7.10.5.4. Recent Developments/ Strategic Initiatives
    • 7.10.6. Lupin
      • 7.10.6.1. Participant's Overview
      • 7.10.6.2. Financial Performance
      • 7.10.6.3. Product Benchmarking
      • 7.10.6.4. Recent Developments/ Strategic Initiatives
    • 7.10.7. Cadila Pharmaceuticals
      • 7.10.7.1. Participant's Overview
      • 7.10.7.2. Financial Performance
      • 7.10.7.3. Product Benchmarking
      • 7.10.7.4. Recent Developments/ Strategic Initiatives
    • 7.10.8. SRS Life Sciences
      • 7.10.8.1. Participant's Overview
      • 7.10.8.2. Financial Performance
      • 7.10.8.3. Product Benchmarking
      • 7.10.8.4. Recent Developments/ Strategic Initiatives
    • 7.10.9. GSK plc.
      • 7.10.9.1. Participant's Overview
      • 7.10.9.2. Financial Performance
      • 7.10.9.3. Product Benchmarking
      • 7.10.9.4. Recent Developments/ Strategic Initiatives
    • 7.10.10. Pfizer Inc.
      • 7.10.10.1. Participant's Overview
      • 7.10.10.2. Financial Performance
      • 7.10.10.3. Product Benchmarking
      • 7.10.10.4. Recent Developments/ Strategic Initiatives
    • 7.10.11. Sanofi
      • 7.10.11.1. Participant's Overview
      • 7.10.11.2. Financial Performance
      • 7.10.11.3. Product Benchmarking
      • 7.10.11.4. Recent Developments/ Strategic Initiatives
    • 7.10.12. Sigma-Aldrich Co.
      • 7.10.12.1. Participant's Overview
      • 7.10.12.2. Financial Performance
      • 7.10.12.3. Product Benchmarking
      • 7.10.12.4. Recent Developments/ Strategic Initiatives